Compare Stocks

Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities.

Comparative Price Performance Over Time

Compare Price & Volume

Company	Current Price	50-Day Moving Average	52-Week Range	Market Cap	Beta	Avg. Volume	Today's Volume
LSDI Lucy Scientific Discovery		$0.03	$0.44 ▼ $12.80	$907K	1.41	640,390 shs	314,500 shs
PALI Palisade Bio	$0.70 -1.9%	$0.72	$0.60 ▼ $4.89	$3.42M	1.36	551,653 shs	117,525 shs
SONN Sonnet BioTherapeutics	$1.12 -2.6%	$1.24	$1.08 ▼ $10.02	$3.64M	0.94	386,626 shs	31,751 shs
SXTP 60 Degrees Pharmaceuticals	$2.30 -5.7%	$2.47	$1.41 ▼ $35.99	$3.59M	2.88	576,955 shs	11,952 shs

5G Stocks: The Path Forward is Profitable

Enter your email address and we'll send you MarketBeat's guide to investing in 5G and which 5G stocks show the most promise.

Get This Free Report

Compare Price Performance

Company	1-Day Performance	7-Day Performance	30-Day Performance	90-Day Performance	1-Year Performance
LSDI Lucy Scientific Discovery	0.00%	0.00%	0.00%	0.00%	-27.00%
PALI Palisade Bio	-1.93%	+13.40%	-8.56%	0.00%	-84.72%
SONN Sonnet BioTherapeutics	-2.61%	-5.88%	-3.03%	-14.50%	+19.79%
SXTP 60 Degrees Pharmaceuticals	-5.74%	+11.11%	0.00%	+23.66%	+72.54%

Compare MarketRank™

Company	Overall Score	Analyst's Opinion	Short Interest Score	Dividend Strength	ESG Score	News and Social Media Sentiment	Company Ownership	Earnings & Valuation
LSDI Lucy Scientific Discovery	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A
PALI Palisade Bio	2.3873 of 5 stars	3.5	2.0	0.0	0.0	2.7	0.0	1.3
SONN Sonnet BioTherapeutics	3.3255 of 5 stars	3.5	3.0	0.0	0.0	3.3	0.0	0.0
SXTP 60 Degrees Pharmaceuticals	2.9987 of 5 stars	3.3	3.0	0.0	0.0	3.3	2.5	0.6

Compare Analyst Forecasts

Company	Consensus Rating Score	Consensus Rating	Consensus Price Target	% Upside from Current Price
LSDI Lucy Scientific Discovery	0.00	N/A	N/A	N/A
PALI Palisade Bio	3.00	Buy	$12.00	1,614.29% Upside
SONN Sonnet BioTherapeutics	3.00	Buy	$20.00	1,685.71% Upside
SXTP 60 Degrees Pharmaceuticals	2.50	Moderate Buy	$7.00	204.35% Upside

Current Analyst Ratings Breakdown

Latest LSDI, SXTP, SONN, and PALI Analyst Ratings

Date	Company	Brokerage	Action	Rating	Price Target
6/27/2025	SXTP 60 Degrees Pharmaceuticals	Weiss Ratings Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Sell (E+) ➝ Sell (E+)
6/11/2025	SXTP 60 Degrees Pharmaceuticals	Weiss Ratings Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Sell (E+) ➝ Sell (E+)
6/2/2025	SXTP 60 Degrees Pharmaceuticals	Ascendiant Capital Markets Subscribe to MarketBeat All Access for the recommendation accuracy rating	Boost Price Target	Buy ➝ Buy	$5.80 ➝ $7.00
5/24/2025	SXTP 60 Degrees Pharmaceuticals	Weiss Ratings Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Sell (E+) ➝ Sell (E+)
5/13/2025	PALI Palisade Bio	Brookline Capital Management Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Buy ➝ Buy	$16.00 ➝ $16.00
5/10/2025	SXTP 60 Degrees Pharmaceuticals	Weiss Ratings Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Sell (E+) ➝ Sell (E+)
4/24/2025	SXTP 60 Degrees Pharmaceuticals	Weiss Ratings Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Sell (E+) ➝ Sell (E+)
4/8/2025	SXTP 60 Degrees Pharmaceuticals	Weiss Ratings Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Sell (E+) ➝ Sell (E+)
4/7/2025	SONN Sonnet BioTherapeutics	Chardan Capital Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Buy ➝ Buy	$20.00 ➝ $20.00
3/28/2025	SONN Sonnet BioTherapeutics	Chardan Capital Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Buy ➝ Buy	$20.00 ➝ $20.00
3/28/2025	SXTP 60 Degrees Pharmaceuticals	HC Wainwright Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Neutral ➝ Neutral

(Data available from 6/28/2022 forward. View 10+ years of historical ratings with our analyst ratings screener.)

Compare Sales & Book Value

Company	Annual Revenue	Price/Sales	Cashflow	Price/Cash	Book Value	Price/Book
LSDI Lucy Scientific Discovery	$16.73K	0.00	N/A	N/A	$2.86 per share	0.00
PALI Palisade Bio	$250K	13.44	N/A	N/A	$2.71 per share	0.26
SONN Sonnet BioTherapeutics	$20K	177.52	N/A	N/A	($0.71) per share	-1.58
SXTP 60 Degrees Pharmaceuticals	$300K	11.27	N/A	N/A	($6.38) per share	-0.36

Compare Profitability & Earnings

Company	Net Income	EPS	Trailing P/E Ratio	Forward P/E Ratio	P/E Growth	Net Margins	Return on Equity (ROE)	Return on Assets (ROA)	Next Earnings Date
LSDI Lucy Scientific Discovery	-$8.99M	-$7.00	N/A	N/A	N/A	N/A	-294.74%	-137.65%	N/A
PALI Palisade Bio	-$14.44M	-$6.80	N/A	N/A	N/A	N/A	-178.96%	-127.35%	8/11/2025 (Estimated)
SONN Sonnet BioTherapeutics	-$7.44M	N/A	0.00	∞	N/A	N/A	-777.92%	-271.32%	8/13/2025 (Estimated)
SXTP 60 Degrees Pharmaceuticals	-$7.95M	-$50.41	N/A	N/A	N/A	-1,947.30%	N/A	-174.90%	8/13/2025 (Estimated)

Latest LSDI, SXTP, SONN, and PALI Earnings

Date	Quarter	Company	Consensus Estimate	Reported EPS	Beat/Miss	Gap EPS	Revenue Estimate	Actual Revenue
5/15/2025	Q1 2025	SXTP 60 Degrees Pharmaceuticals	-$1.31	-$1.56	-$0.25	-$1.56	$0.15 million	$0.18 million
5/13/2025	Q2 2025	SONN Sonnet BioTherapeutics	-$0.92	-$0.89	+$0.03	-$0.89	N/A	N/A
5/12/2025	Q1 2025	PALI Palisade Bio	-$0.84	-$0.47	+$0.37	-$0.47	N/A	N/A

Compare Dividends

Company	Annual Payout	Dividend Yield	3-Year Dividend Growth	Payout Ratio	Years of Consecutive Growth
LSDI Lucy Scientific Discovery	N/A	N/A	N/A	N/A	N/A
PALI Palisade Bio	N/A	N/A	N/A	N/A	N/A
SONN Sonnet BioTherapeutics	N/A	N/A	N/A	N/A	N/A
SXTP 60 Degrees Pharmaceuticals	N/A	N/A	N/A	N/A	N/A

Compare Debt

Company	Debt-to-Equity Ratio	Current Ratio	Quick Ratio
LSDI Lucy Scientific Discovery	N/A	0.38	0.38
PALI Palisade Bio	N/A	2.84	2.84
SONN Sonnet BioTherapeutics	N/A	1.03	1.03
SXTP 60 Degrees Pharmaceuticals	N/A	3.14	2.71

Compare Ownership

Institutional Ownership

Company	Institutional Ownership
LSDI Lucy Scientific Discovery	72.61%
PALI Palisade Bio	11.79%
SONN Sonnet BioTherapeutics	9.45%
SXTP 60 Degrees Pharmaceuticals	7.96%

Insider Ownership

Company	Insider Ownership
LSDI Lucy Scientific Discovery	N/A
PALI Palisade Bio	3.28%
SONN Sonnet BioTherapeutics	2.00%
SXTP 60 Degrees Pharmaceuticals	10.27%

Compare Miscellaneous Stats

Company	Employees	Shares Outstanding	Free Float	Optionable
LSDI Lucy Scientific Discovery	2	1.77 million	N/A	Not Optionable
PALI Palisade Bio	10	4.80 million	4.64 million	Not Optionable
SONN Sonnet BioTherapeutics	10	3.17 million	3.10 million	Not Optionable
SXTP 60 Degrees Pharmaceuticals	3	1.47 million	1.32 million	Not Optionable

LSDI, SXTP, SONN, and PALI Headlines

Recent News About These Companies

Weiss Ratings Reiterates Sell (E+) Rating for 60 Degrees Pharmaceuticals (NASDAQ:SXTP)

June 28 at 2:28 AM | americanbankingnews.com

60 Degrees Pharmaceuticals, Inc. (NASDAQ:SXTP) Director Cheryl Xu Acquires 5,000 Shares

June 6, 2025 | insidertrades.com

60 Degrees Pharmaceuticals Reports Significant Discrepancy in Babesiosis Case Estimates and Plans for New Drug Application in 2026

June 5, 2025 | nasdaq.com

60 Degrees Pharmaceuticals Expands Options for Malaria Prevention with Introduction of ARAKODA® (tafenoquine) 8-Count Bottle Format

June 4, 2025 | globenewswire.com

Babesiosis Incidence in U.S. 10x Higher Than CDC Estimates, According to Insurance Claims Study Commissioned by 60 Degrees Pharmaceuticals

June 3, 2025 | globenewswire.com

60 Degrees Pharmaceuticals Announces First Quarter 2025 Results

May 15, 2025 | globenewswire.com

Babesiosis Disease Burden in United States is Substantially Higher Than Official Estimates, According to Preliminary Results of 60 Degrees Pharma Survey

April 22, 2025 | globenewswire.com

Why 60 Degrees Pharmaceuticals, Inc. (SXTP) Went Down On Thursday?

April 10, 2025 | insidermonkey.com

Geoff Dow, PhD, Infectious Disease Product Development Expert, to Discuss Babesiosis at Healing Lyme Summit, April 15-21

April 10, 2025 | globenewswire.com

Geoff Dow, PhD, Infectious Disease Product Development Expert, to Discuss Babesiosis at Healing Lyme Summit, April 15-21

April 10, 2025 | globenewswire.com

Sixty Degrees Pharmaceuticals Announces Patent License Agreement to Advance Development of Tafenoquine for Babesiosis Treatment and Prevention with Yale School of Medicine and Yale School of Public Health

April 8, 2025 | globenewswire.com

60 Degrees Pharmaceuticals, Inc.

April 4, 2025 | uk.investing.com

60 Degrees Pharmaceuticals and Fathom Holdings Interviews to Air on the RedChip Small Stocks, Big Money(TM) Show on Bloomberg TV

February 21, 2025 | accessnewswire.comA

60 Degrees Pharmaceuticals announces 1-for-5 reverse stock split

February 20, 2025 | markets.businessinsider.com

60 Degrees Pharmaceuticals, Inc. Announces 1-for-5 Reverse Stock Split to Comply with Nasdaq Listing Requirements

February 20, 2025 | quiverquant.comQ

60 Degrees Pharmaceuticals, Inc. Announces 1:5 Reverse Stock Split

February 20, 2025 | globenewswire.com

60 Degrees says FDA does not object to tafenoquine import plan

February 11, 2025 | markets.businessinsider.com

60 Degrees Pharmaceuticals, Inc. Receives FDA Approval for Importing KODATEF® as Preemptive Measure for ARAKODA® Supply Stability

February 11, 2025 | quiverquant.comQ

Sixty Degrees Pharmaceuticals to Ensure Continuity of Tafenoquine Supply in U.S. by Importing Limited Quantity of KODATEF®

February 11, 2025 | globenewswire.com

Insiders Give Up US$71k As 60 Degrees Pharmaceuticals Stock Drops To US$0.55

February 9, 2025 | finance.yahoo.com

New MarketBeat Followers Over Time

Media Sentiment Over Time

LSDI, SXTP, SONN, and PALI Company Descriptions

Lucy Scientific Discovery NASDAQ:LSDI

Lucy Scientific Discovery Inc., an early stage psychotropics contract manufacturing company, engaged in the research, manufacturing, and commercialization of psychedelic products. The company offers biological raw materials, active pharmaceutical ingredients (APIs), and finished biopharmaceutical products. It also develops and produces highly controlled agricultural grow environments for plant manufacturing and replication applications. The company was formerly known as Hollyweed North Cannabis Inc. and changed its name to Lucy Scientific Discovery Inc. in May 2021. Lucy Scientific Discovery Inc. was incorporated in 2017 and is headquartered in Victoria, Canada.

Palisade Bio NASDAQ:PALI

$0.70 -0.01 (-1.93%)

Closing price 06/27/2025 04:00 PM Eastern

Extended Trading

$0.69 -0.01 (-1.00%)

As of 06/27/2025 06:52 PM Eastern

Palisade Bio, Inc., a clinical-stage biopharmaceutical company, focuses on focuses on developing therapeutics that protect the integrity of the intestinal barrier in the United States. The company's lead therapeutic candidate is PALI-2108, a prodrug PDE4 inhibitor, currently under pre-clinical development as a therapeutic for patients living with inflammatory bowel diseases, including ulcerative colitis and Crohn's disease (CD), as well as develops PALI-1908, an oral, selective PDE4 inhibitor prodrug that is locally bioactivated in the terminal ileum of CD patients, currently in the research stage. It has a research collaboration and license agreement with Giiant Pharma, Inc. for the development, manufacture, and commercialization of its compounds; a license agreement with the Regents of the University of California; a co-development and distribution agreement with Newsoara Biopharma Co., Ltd; and a transformative strategic collaboration with Strand Life Sciences for advancing precision medicine for ulcerative colitis therapy. The company is based in Carlsbad, California.

Sonnet BioTherapeutics NASDAQ:SONN

$1.12 -0.03 (-2.61%)

Closing price 06/27/2025 04:00 PM Eastern

Extended Trading

$1.12 +0.00 (+0.45%)

As of 06/27/2025 06:43 PM Eastern

Sonnet BioTherapeutics Holdings, Inc., a biotechnology company, owns a platform for biologic medicines of single or bifunctional action. The company develops fully human albumin binding technology, which utilizes human single chain antibodies fragment that binds to and hitch-hikes on human serum albumin for transport to target tissues. Its lead product candidate is SON-1010, a fully human single-chain version of interleukin 12 that is in Phase 1b/2a clinical trial for the treatment of solid tumor indications, including ovarian cancer, non-small cell lung cancer, and head and neck cancer. The company is also developing SON-080, a fully human version of interleukin 6, which is in Phase 1b/I2a clinical trail to treat chemotherapy-induced peripheral neuropathy and diabetic peripheral neuropathy; and SON-1210, a bispecific compound for solid tumor indications, including colorectal cancer. It has a license agreement with New Life Therapeutics Pte, LTD. to develop and commercialize pharmaceutical preparations containing a specific recombinant human interleukin-6; and strategic development collaboration with Sarcoma Oncology Center to advance SON-1210. The company is headquartered in Princeton, New Jersey.

60 Degrees Pharmaceuticals NASDAQ:SXTP

$2.30 -0.14 (-5.74%)

Closing price 06/27/2025 04:00 PM Eastern

Extended Trading

$2.16 -0.14 (-5.87%)

As of 06/27/2025 06:50 PM Eastern

60 Degrees Pharmaceuticals, Inc., a specialty pharmaceutical company, engages in the development and commercialization of therapies for the prevention and treatment of infectious diseases in the United States. The company offers Arakoda for malaria preventative treatment. It also engages in the development of Tafenoquine (Arakoda regimen) that is in Phase IIb clinical trial for COVID-19 indications; Tafenoquine, which is in phase IIA clinical trials for babesiosis, fungal pneumonias, and candidiasis disease; and Celgosivir for respiratory viruses and dengue. The company was founded in 2010 and is headquartered in Washington, the District of Columbia.

More Stock Comparisions from MarketBeat

More Stock Ideas from MarketBeat

Stock Lists

Low Priced Stocks

Stocks By Exchange

Latest Stock Ideas

Get 30 Days of MarketBeat All Access for Free

Start Your 30-Day Trial

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Compare Stocks

Comparative Price Performance Over Time